These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 19174316

  • 21. Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes.
    Bellia A, Rizza S, Galli A, Fabiano R, Donadel G, Lombardo MF, Cardillo C, Sbraccia P, Tesauro M, Lauro D.
    Atherosclerosis; 2010 May; 210(1):199-201. PubMed ID: 20018286
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
    Vaverkova H, Farnier M, Averna M, Missault L, Viigimaa M, Dong Q, Shah A, Johnson-Levonas AO, Brudi P.
    Cardiovasc Ther; 2012 Apr; 30(2):61-74. PubMed ID: 20626402
    [Abstract] [Full Text] [Related]

  • 24. Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia.
    Ott C, Schlaich MP, Schmidt BM, Titze SI, Schäufele T, Schmieder RE.
    Atherosclerosis; 2008 Feb; 196(2):704-11. PubMed ID: 17298834
    [Abstract] [Full Text] [Related]

  • 25. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
    Betteridge DJ, Gibson JM, Sager PT.
    Am J Cardiol; 2007 Oct 15; 100(8):1245-8. PubMed ID: 17920365
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Is endothelial dysfunction reversible?
    Schmieder RE, Schobel HP.
    Am J Cardiol; 1995 Jul 13; 76(2):117A-121A. PubMed ID: 7604785
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Pharmacological and clinical profile of rosuvastatin calcium (Crestor)].
    Ohfuji K, Yano S, Yamaguchi M, Smith G, Hirata M, Shimada H, Izuishi K, Shinagawa J, Matsunaga K.
    Nihon Yakurigaku Zasshi; 2005 Sep 13; 126(3):213-9. PubMed ID: 16272766
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function.
    Pirro M, Schillaci G, Romagno PF, Mannarino MR, Bagaglia F, Razzi R, Pasqualini L, Vaudo G, Mannarino E.
    J Cardiovasc Pharmacol Ther; 2009 Mar 13; 14(1):14-21. PubMed ID: 19158317
    [Abstract] [Full Text] [Related]

  • 32. Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
    Glueck CJ, Rawal B, Khan NA, Yeramaneni S, Goldenberg N, Wang P.
    Metabolism; 2009 Feb 13; 58(2):233-8. PubMed ID: 19154957
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes.
    Oltman CL, Kleinschmidt TL, Davidson EP, Coppey LJ, Lund DD, Yorek MA.
    Vascul Pharmacol; 2008 Jan 13; 48(1):47-53. PubMed ID: 18164667
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Rosuvastatin treatment improves arterial stiffness with lowering blood pressure in healthy hypercholesterolemic patients.
    Oh PC, Han SH, Koh KK, Lee K, Seo JG, Suh SY, Ahn T, Choi IS, Shin EK.
    Int J Cardiol; 2014 Oct 20; 176(3):1284-7. PubMed ID: 25135328
    [No Abstract] [Full Text] [Related]

  • 37. An update on the benefits and risks of rosuvastatin therapy.
    Toth PP.
    Postgrad Med; 2014 Mar 20; 126(2):7-17. PubMed ID: 24685964
    [Abstract] [Full Text] [Related]

  • 38. Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients.
    Santini E, Madec S, Corretti V, Ferrannini E, Solini A.
    J Endocrinol Invest; 2008 Jul 20; 31(7):660-5. PubMed ID: 18787388
    [Abstract] [Full Text] [Related]

  • 39. Endothelium-dependent responses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined.
    Esper RJ, Machado R, Vilariño J, Cacharrón JL, Ingino CA, García Guiñazú CA, Bereziuk E, Bolaño AL, Suarez DH.
    Am Heart J; 2000 Oct 20; 140(4):684-9. PubMed ID: 11011346
    [Abstract] [Full Text] [Related]

  • 40. Balancing the cardiometabolic benefits and risks of statins.
    Watts GF, Ooi EM.
    Lancet; 2012 Aug 11; 380(9841):541-3. PubMed ID: 22883491
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.